ASCO preview carries MacroGenics to $1B valuation

MacroGenics more than tripled its share price Wednesday after President and CEO Scott Koenig previewed ASCO presentations on the company’s 1Q20 earnings call Tuesday and provided updates on two other clinical programs.

MacroGenics Inc. (NASDAQ:MGNX) gained $17.55 (231%) to $25.15, pushing its market cap to $1.2 billion from $373.4 million...